Novo Nordisk (NVO) Stock Plunges 8%: Should Investors Be Worried?

Key Takeaways

• Shares of NVO plummeted almost 8% on Monday, marking the most significant one-day decline since February
• CEO Mike Doustdar announced the company’s openness to acquisitions for addressing development pipeline weaknesses, especially in heart disease treatments
• The blockbuster drugs Wegovy and Ozempic, representing approximately 75% of revenue, will lose patent protection in the early 2030s
• Management aims to launch 5+ blockbuster medications by decade’s end and generate over $23 billion in additional revenue by 2035
• Share buybacks continue with DKK 9.63 billion in B shares repurchased under the DKK 15 billion program

Shares of Novo Nordisk experienced a sharp decline of nearly 8% on Monday following a capital markets presentation that left investors questioning the pharmaceutical giant’s future drug development strategy. Trading at $39.80, down $3.44, the stock continued its downward trajectory on Tuesday.

Novo Nordisk A/S, NVO

The market’s negative response stemmed from disappointment that Novo’s projected goals appeared to reflect current market expectations rather than exceeding them.

CEO Mike Doustdar addressed the market’s lukewarm reception during an interview on CNBC’s “Squawk Box Europe,” stating: “We talked about diversification of the company, but yet the reaction tells me that there’s still some work to do in convincing some of the investors.”

Doustdar further recognized the company’s trust deficit with investors. “What we have learned the last couple of years is overpromising and underdelivering loses trust very quickly,” he told Bloomberg TV.

Management outlined ambitious goals including launching more than five blockbuster therapies by 2030 and generating upwards of $23 billion in additional revenue by 2035. Wall Street remained skeptical.

Looming Patent Expirations Spark Investor Anxiety

The fundamental concern revolves around impending patent cliffs. Ozempic and Wegovy, which collectively represent roughly three-quarters of Novo’s total sales, will lose exclusivity protection in both the United States and European markets during the early 2030s.

This timeline creates urgency to develop a robust product portfolio capable of offsetting that revenue loss. Doustdar revealed the company is actively pursuing acquisition opportunities to strengthen its pipeline, particularly in therapeutic areas complementary to obesity such as cardiovascular medicine.

The cardiovascular expansion strategy gained importance after ziltivekimab, Novo’s experimental heart drug candidate, failed to demonstrate reduction in heart attack risk during clinical testing this year. Doustdar indicated the company is now evaluating whether strategic acquisitions could address this therapeutic gap.

He observed that attractive acquisition targets specifically in obesity are scarce, prompting a strategic pivot toward complementary disease areas for M&A activity.

Market Watches CagriSema Development

CagriSema, Novo’s next-generation obesity treatment candidate, remains under close scrutiny from investors. Doustdar expressed confidence that it would become one of the company’s most successful product launches in the coming year.

Nevertheless, expectations have been moderated. In direct comparison trials conducted earlier this year, CagriSema produced less weight reduction than Eli Lilly’s competing drug Zepbound, creating challenges for Novo’s commercial strategy and market positioning.

Regarding capital allocation, Novo has maintained its share repurchase initiative. During the period from September 14 to 18, 2026, the company acquired an additional 1.09 million B shares. Cumulative repurchases since February have reached 34.17 million B shares totaling DKK 9.63 billion, representing progress toward the authorized DKK 15 billion buyback program.

The latest Wall Street analyst rating on NVO is a Hold recommendation with a $47.00 price objective. The company’s current market capitalization stands at roughly $191.7 billion.